Page 2 - Secondary Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Puerto ricoUnited kingdomUnited statesFrance generalSan diegoMelinda gooderhamLoretta fiorilloJessica akopyanPonda motsepe ditshegoCallis duffinKate meyerJustin claeysJolla institute for immunologyNational psoriasis foundationTeneobio incAmerican academy of dermatology

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight.

Drug administrationLigand pharmaceuticals incorporatedTherapeutics incStudy achieves primarySecondary endpointsBody weightPlacebo adjusted mean weight lossFrom baselineObserved afterWeek studyTreatment emergent adverse events considered mildCall scheduledViking therapeuticsBody weight followingOnce weekly dosingCommon gastrointestinal

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesLota zothRichard bryceRyan dawsDerivatized oligochitosanAlex nicholsJason hansonForbion european acquisition corpPublic companyClinical program progressCompany audit committee chairGene holdings incCompany annual report on formExchange commissionCompany board of directorsForbion european acquisition corporation

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with.

United statesAlex nicholsRichard bryceRyan dawsLota zothDerivatized oligochitosanJason hansonPublic companyForbion european acquisition corporationClinical program progressCompany board of directorsExchange commissionForbion european acquisition corpCompany audit committee chairGene holdings incCompany annual report on form

Gannex s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Gannex s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongHong kong stock exchangePrnewswire gannex pharma company ltdGannex pharma co ltdSagimet biosciences incAscletis pharma incSagimet biosciencesPharma company ltdAscletis pharmaSignificance achievedPrimary endpointsSecondary endpointsArtificial intelligence